Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
Mayo Clinic
ClinicalTrials.gov Identifier:
NCT00416624
First received: December 27, 2006
Last updated: March 16, 2011
Last verified: March 2011

December 27, 2006
March 16, 2011
May 2007
June 2009   (final data collection date for primary outcome measure)
Hematopoietic response (hemoglobin rise of 2 g/dL from baseline OR achievement of hemoglobin within the goal range) [ Time Frame: 20 weeks ]
the proportion of patients who exhibit a hematopoietic response (defined as Hb rise >2 g/dL from baseline or achieving Hb ≥ 11.5 g/dL, whichever occurs first, in the absence of RBC transfusions within 14 days of measurement) during the treatment period
Hematopoietic response (hemoglobin rise of 2 g/dL from baseline OR achievement of hemoglobin of at least 12 g/dL)
Complete list of historical versions of study NCT00416624 on ClinicalTrials.gov Archive Site
  • Weekly change in hemoglobin levels [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    To compare the effects of the 3 different epoetin alfa dosing schedules and an every-3-weeks darbepoetin alfa
  • Time required to achieve hemoglobin levels within the goal range [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa
  • Proportion of patients requiring red blood cell (RBC) transfusions and the number of transfusions required [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa
  • Dose reduction in each regimen [ Designated as safety issue: No ]
    To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa
  • Adverse events as measured by CTCAE v3.0 [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa
  • Quality of life as measured by Functional Assessment of Cancer Therapy Scales for Anemia, Linear Analogue Self Assessment measures, Brief Fatigue Inventory, and Symptom Distress Scale at baseline and at 4, 8, 16, and 24 weeks [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa
  • Mean hemoglobin increment week by week [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    To compare the effects of the 3 different epoetin alfa dosing schedules and an every-3-weeks darbepoetin alfa
  • Weekly change in hemoglobin levels
  • Hemoglobin changes from baseline to weeks 4, 7, 10, 13, and 16
  • Time required to achieve hemoglobin levels of at least 12.0 g/dL
  • Proportion of patients requiring red blood cell (RBC) transfusions and the number of transfusions required
  • Dose reduction in each regimen
  • Adverse events as measured by CTCAE v3.0
  • Quality of life as measured by Functional Assessment of Cancer Therapy Scales for Anemia, Linear Analogue Self Assessment measures, Brief Fatigue Inventory, and Symptom Distress Scale at baseline and at 4, 8, 16, and 24 weeks
Not Provided
Not Provided
 
Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy
RC05CB A Pilot, Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week-Epoetin Alfa and Every 3-Week Darbepoetin Alfa

RATIONALE: Epoetin alfa and darbepoetin alfa may cause the body to make more red blood cells. They are used to treat anemia caused by chemotherapy in patients with cancer.

PURPOSE: This randomized clinical trial is studying four different schedules of epoetin alfa or darbepoetin alfa to compare how well they work in treating patients with anemia caused by chemotherapy.

OBJECTIVES:

Primary

  • Compare the relative efficacy of four different erythropoietic agent dosing schedules comprising epoetin alfa or darbepoetin alfa, in terms of the proportion of patients with chemotherapy-associated anemia who achieve a weekly and overall hematopoietic response.

Secondary

  • Compare the effect of these regimens on the mean hemoglobin increment measured weekly from baseline to 15 weeks in patients with a baseline hemoglobin of less than or equal to 10.5 g/dL.
  • Compare the time required to achieve hemoglobin levels within the goal range 11.0-12.0 g/dL in patients treated with these regimens.
  • Compare the effect of these regimens on the proportion of patients requiring red blood cell transfusions and on the number of transfusions required.
  • Compare the weekly change in hemoglobin in patients treated with these regimens.
  • Compare the need for dose reduction in patients treated with these regimens.
  • Compare the adverse event profiles of these regimens in these patients.
  • Compare quality of life of patients treated with these regimens.

OUTLINE: This is a randomized, unblinded, pilot study. Patients are stratified according to severity of anemia (mild [hemoglobin ≥ 9.5 g/dL] vs severe [hemoglobin < 9.5 g/dL]), platinum-containing regimen (yes vs no), and tumor type (nonmyeloid hematologic malignancy vs solid tumor). Patients are randomized to 1 of 4 treatment arms.

  • Arm I: Patients receive epoetin alfa subcutaneously (SC) on day 1. Treatment repeats weekly for up to 15 courses in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive epoetin alfa SC on day 1 (at a higher dose than in arm I). Treatment repeats every 3 weeks for up to 5 courses in the absence of disease progression or unacceptable toxicity.
  • Arm III: Patients receive epoetin alfa SC on day 1 (at a higher dose than in arm II). Treatment repeats every 3 weeks for up to 5 courses in the absence of disease progression or unacceptable toxicity.
  • Arm IV: Patients receive darbepoetin alfa SC on day 1. Treatment repeats every 3 weeks for up to 5 courses in the absence of disease progression or unacceptable toxicity.

Hemoglobin levels are monitored throughout the study on a weekly basis and before each drug dose is administered. Drug dosing is adjusted (e.g., held, reduced, resumed at a lower dose) as needed to maintain hemoglobin values within the desired ranges.

Quality of life is assessed at baseline and at weeks 4, 7, 10, 13, and 16.

After completion of study treatment, patients are followed at 30 days.

PROJECTED ACCRUAL: A total of 320 patients will be accrued for this study.

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
  • Anemia
  • Leukemia
  • Lymphoma
  • Lymphoproliferative Disorder
  • Multiple Myeloma and Plasma Cell Neoplasm
  • Precancerous Condition
  • Unspecified Adult Solid Tumor, Protocol Specific
  • Drug: darbepoetin alfa
  • Drug: epoetin alfa
  • Procedure: fatigue assessment and management
  • Procedure: quality-of-life assessment
  • Experimental: Epoetin alfa - 40000 units
    40,000 Units
    Interventions:
    • Drug: darbepoetin alfa
    • Drug: epoetin alfa
    • Procedure: fatigue assessment and management
    • Procedure: quality-of-life assessment
  • Experimental: Epoetin alfa - 80000 units
    80,000 Units
    Interventions:
    • Drug: darbepoetin alfa
    • Drug: epoetin alfa
    • Procedure: fatigue assessment and management
    • Procedure: quality-of-life assessment
  • Experimental: Epoetin alfa - 120000 Units
    120,000 Units
    Interventions:
    • Drug: darbepoetin alfa
    • Drug: epoetin alfa
    • Procedure: fatigue assessment and management
    • Procedure: quality-of-life assessment
  • Experimental: Darbepoetin alfa***
    500 mcg
    Interventions:
    • Drug: darbepoetin alfa
    • Drug: epoetin alfa
    • Procedure: fatigue assessment and management
    • Procedure: quality-of-life assessment
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
320
June 2009
June 2009   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Diagnosis of solid tumor or nonmyeloid hematologic malignancy (e.g., plasma cell dyscrasia or lymphoproliferative disorder)

    • No nonmelanomatous skin cancer
  • Hemoglobin ≤ 10.5 g/dL
  • Ferritin > 20 ng/mL (i.e., not obviously iron deficient)
  • Planning to receive ≥ 12 weeks of anticancer chemotherapy

    • Biological therapy (e.g., hypomethylating agents, monoclonal antibodies, or small molecule pathway inhibitors) with an individual or cumulative regimen incidence of grade 3 or 4 anemia > 10% is considered chemotherapy for purposes of this study
  • No known anemia secondary to any of the following:

    • Cyanocobalamin (vitamin B_12) or folic acid deficiency
    • Gastrointestinal bleeding within the past 2 weeks
    • Hemolysis
    • Myelodysplastic syndromes, myeloproliferative disorders, or acute myeloid leukemia
  • No primary hematologic disorder causing chronic moderate to severe anemia (e.g., congenital dyserythropoietic anemia, homozygous hemoglobin S disease or compound heterozygous sickling states, or thalassemia major)

    • Carriers of these disease states allowed provided they are not anemic prior to cancer diagnosis

PATIENT CHARACTERISTICS:

  • ECOG performance status 0-2
  • Life expectancy ≥ 6 months
  • Not pregnant or nursing

    • No delivery of a baby of ≥ 18 weeks estimated gestational age within the past 3 months (90 days)
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Weight > 40.0 kg and < 150.0 kg
  • No known hypersensitivity to epoetin alfa, darbepoetin alfa, mammalian-cell derived products, or human albumin
  • No uncontrolled hypertension, defined as systolic blood pressure (BP) ≥ 180 mm Hg and/or diastolic BP ≥ 100 mm Hg, despite medical therapy
  • No pulmonary emboli and/or deep vein thrombosis within the past 12 months

    • Patients actively receiving warfarin for a minimum of 4 weeks are exempted from this requirement
    • Prior superficial thrombophlebitis allowed
  • No cerebrovascular accident, ischemic stroke, acute coronary syndrome (e.g., unstable angina or Q-wave or non-Q wave myocardial infarction), or other arterial or venous thrombotic events within the past 6 months
  • No history of chronic hypercoagulable disorders (e.g., activated protein C resistance, anti-cardiolipin disorder, protein C deficiency, or protein S deficiency)

    • Patients receiving anticoagulation therapy (warfarin or acetylsalicyclic acid [aspirin] at a dose of ≥ 325 mg/day) for these conditions are eligible provided therapy is continued during the study period
  • History of previously treated seizures allowed provided the patient has been seizure-free for a minimum of 3 months

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • More than 1 year since prior peripheral blood stem cell, bone marrow, or cord blood transplantation
  • More than 14 days since prior red blood cell transfusion
  • More than 14 days since prior major surgery, including, but not limited to, any of the following:

    • Amputation
    • Invasion of a body cavity or of the central nervous system using a scalpel, saw, or laser cutting tool
    • Resection of a body part (or parts), whether solid or liquid tissue or both, that includes ≥ 1% of a patient's preoperative weight
    • The following are not considered major surgery:

      • Diagnostic/therapeutic thoracentesis or paracentesis
      • Diagnostic skin biopsy
      • Digit or fingernail/thumbnail resection or laceration repair under local anesthesia
      • Diagnostic fat aspiration
      • Otic irrigation to remove cerumen impaction
      • Tympanocentesis
      • Uncomplicated dental extraction
      • Uncomplicated tonsillectomy
      • Laser corneal remodeling for refraction purposes
      • Cosmetic or therapeutic eyelid surgery
      • Bone marrow aspiration and biopsy
  • More than 10 weeks since prior darbepoetin alfa, epoetin alfa, or any investigational form of erythropoietin (e.g., gene-activated erythropoietin or novel erythropoiesis stimulating protein)
  • No planned stem cell transplantation within the next 4 months (18 weeks)
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00416624
CDR0000522677, P30CA015083, RC05CB, 06-002991, EPOANE3015
Yes
Charles Lawrence Loprinzi, M.D., Mayo Clinic Cancer Center
Mayo Clinic
National Cancer Institute (NCI)
Study Chair: Charles L. Loprinzi, M.D. Mayo Clinic
Mayo Clinic
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP